Migraine, a severe headache accompanied by nausea, photophobia and phonophobia, can be controlled with pharmacological as well as non-pharmacological therapies. In biofeedback, patients learn to voluntarily modify their bodily reactions through feedback mediated awareness of physiological parameters, thus promoting relaxation, reducing stress and preventing migraine attacks. We aim to assess the efficacy of biofeedback on adult patients with migraine. Study protocol was registered on PROSPERO with reference number CRD42024606671. PubMed, Embase and Google Scholar were searched for randomized controlled trials from 2000 to 2024 in English that have evaluated the administration of biofeedback to the adult patients with migraine. High quality studies were included after RoB 2.0 Risk of Bias assessment. ANOVA with inverse variance weighting was used to compare mean differences across groups with 95% confidence interval. Nine studies (558 participants) and three studies (278 participants) respectively qualified for comparison of biofeedback with waiting list control and active treatment. Biofeedback significantly reduced headache frequency and severity compared to waiting-list control. However, it showed no significant difference in headache frequency when compared to active treatments such as pharmacotherapy or cognitive behavioral therapy. Additionally, improvements in migraine-related disability, depression, anxiety, and quality of life were reviewed. This meta-analysis confirms that biofeedback is an effective non-pharmacological intervention for reducing headache frequency and severity in migraines. Additionally, it appears to provide synergistic benefits when combined with pharmacotherapy. However, future studies should focus on the cost-effectiveness and accessibility of home-based and app-based biofeedback to determine its broader clinical applicability.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ctim.2025.103153 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nicotine replacement therapy as a smoking cessation tool for adolescents: an update.
Front Psychiatry
February 2025
Respiratory Failure Unit, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Background: Adolescent smoking is a significant public health concern, as early nicotine addiction leads to more severe addiction and reduced cessation success during adulthood. While nicotine replacement therapy (NRT) is an effective smoking cessation tool in adults, its efficacy in adolescents is less clear.
Objective: This systematic review evaluates the effectiveness and safety of NRT for smoking cessation in adolescents.
Dengue in patients with kidney transplant: a systematic review.
Infez Med
March 2025
Masters' Program of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, Universidad Cientifica del Sur, Lima, 15067, Peru.
Introduction: The incidence of dengue and its complications increases globally, mainly in areas where it is endemic; however, little literature evaluates outcomes in kidney transplant recipients (KTR). The present analysis aimed to determine the incidence, signs and symptoms, and allograft dysfunction in dengue-infected KTR.
Methods: Systematic review of the literature following PRISMA 2020 indications with studies included until November 24, 2023.
Efficacy and continuability of 675 mg fremanezumab administration over 2 years.
J Headache Pain
March 2025
Japanese Red Cross Society Shizuoka Hospital, Shizuoka, Japan.
Background: Real-world data on the long-term adherence to- and efficacy of fremanezumab 675 mg quarterly dosing remain scarce. Our study evaluated the efficacy of- and patient adherence to 675 mg fremanezumab for episodic migraine (EM) and chronic migraine (CM) over 2 years and analyzed the reasons for discontinuation.
Methods: Among patients attending our headache outpatient clinic, those aged ≥ 15 years who commenced fremanezumab 675 mg quarterly dose schedule from November 2021 to June 2022 were enrolled in this single-center observational study.
The burden of migraine in Mexico: a database analysis of migraine-related visits to emergency departments in Mexico's ministry of health (MMoH) hospitals.
Expert Rev Neurother
March 2025
Evidence Generation Medical Affairs, Pfizer, Emerging Markets, Brazil.
Background: The burden of migraine in Mexican Emergency Department (ED) settings remains understudied. This study aimed to determine the frequency of migraine-related ED visits within the ED Mexican Ministry of Health's (MMoH) database and analyze their demographics and treatment patterns.
Research Design And Methods: This retrospective study analyzed MMoH database of ED visits between 2013 and 2022.
''Wait and See'' as a Treatment Option for a Rathke's Cleft Cyst Apoplexy in Pediatric Population: A Case Report.
Int J Endocrinol Metab
January 2024
Department of Endocrinology Diabetology and Nutrition, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy of Oujda, Mohamed the First University, Oujda, Morocco.
Introduction: Rathke cleft cyst apoplexy is exceedingly rare, particularly in infants. The most prevalent clinical manifestations include headaches, visual field defects, and endocrine dysfunction. Treatment options range from surgery to conservative methods, taking into consideration the balance of benefits and risks, especially during critical life stages such as childhood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!